Brain tumour response rates: complete response (CR) and partial response (PR) combinedNo. of participants: 847(6 RCTs)
Pembrolizumab probably leads to higher response rate (partial and complete response) compared with chemotherapy (moderate certainty).
1 finding from 1 review
Treatment‐related mortality
Pembrolizumab showed no clear difference in treatment‐related mortality compared with chemotherapy (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events
Pembrolizumab showed no clear difference in discontinuation due to adverse event compared with chemotherapy (low certainty).
1 finding from 1 review
Serious adverse events (irrespective of attribution to treatment)
Pembrolizumab may leads to lower serious adverse events (irrespective of attribution to treatment) compared with chemotherapy (low certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Interferon‐α combined with targeted therapies may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapy (low certainty).
1 finding from 1 review
1‐year mortality · previously untreated patients with mRCC
Interferon‐α combined with targeted therapies showed no clear difference in 1‐year mortality compared with standard targeted therapy (moderate certainty).
1 finding from 1 review
Quality of life · previously untreated patients with mRCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · hormone‐sensitive prostate cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · hormone‐sensitive prostate cancer
Degarelix showed no clear difference in serious adverse events compared with standard androgen suppression therapy (low certainty).
1 finding from 1 review
Quality of life · hormone‐sensitive prostate cancer
1 finding from 1 review
Cancer‐specific survival (24 months) (Number of cancer‐related deaths) · hormone‐sensitive prostate cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular events · hormone‐sensitive prostate cancer
It is very uncertain whether degarelix changes cardiovascular events compared with standard androgen suppression therapy (very low certainty).
1 finding from 1 review
Injection site pain · hormone‐sensitive prostate cancer
Degarelix probably leads to higher injection site pain compared with standard androgen suppression therapy (moderate certainty).
1 finding from 1 review
Stone‐free rate
It is very uncertain whether shock wave lithotripsy changes stone‐free rate compared with dissolution therapy (very low certainty).
1 finding from 1 review
Serious adverse events or complications of treatment
It is very uncertain whether shock wave lithotripsy changes serious adverse events or complications of treatment compared with dissolution therapy (very low certainty).
1 finding from 1 review
Secondary procedures for residual fragments
It is very uncertain whether shock wave lithotripsy changes secondary procedures for residual fragments compared with dissolution therapy (very low certainty).
1 finding from 1 review
Hospital stay — not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Urological symptom scores
1 finding from 1 review
Quality of life
1 finding from 1 review
Treatment withdrawal
It is very uncertain whether naftopidil changes treatment withdrawals for any reason compared with eviprostat (phytotherapy) (very low certainty).
1 finding from 1 review